Background: Pentraxin 3 is an inflammatory biomarker whose serum level is increased during acute myocardial infarction (AMI). The aim of this study was to measure the serum pentraxin-3 level in anterior ST-segment ele...Background: Pentraxin 3 is an inflammatory biomarker whose serum level is increased during acute myocardial infarction (AMI). The aim of this study was to measure the serum pentraxin-3 level in anterior ST-segment elevation myocardial infarction (STEMI), to investigate correlation with the left ventricular (LV) systolic function assessed by speckle tracking echocardiography, and compare with the well-established cardiac biomarkers of myocardial injury such as troponin-I. Methods: Serum pentraxin-3 level was measured by ELISA in 50 patients with anterior STEMI. LV strain was measured by speckle tracking echocardiography. The results were compared to twenty sex- and age-matched persons who had history of stable angina and normal LV ejection fraction (LVEF). Results: Serum level of pentraxin-3 was significantly higher in STEMI patients in comparison to the control group (8.3 ± 3.1 versus 3.4 ± 1.2 ng/ml, p 0.001). Average LV global longitudinal strain (GLS) was reduced in STEMI patients in comparison to control subjects (11.2 ± 2.4 versus 20.2 ± 2.1, p 0.001). In addition, there was a significant negative correlation between serum pentraxin-3 level and LVEF (r = -0.557, p 0.001) and the average LVGLS (r =-0.529, p 0.001). Serum pentraxin-3 cutoff value > 8.3 ng/ml had sensitivity of 81.8% and specificity of 86.4% to detect LVEF less than 50% (p 0.001). While, peak cardiac troponin-I level > 34 ng/ml was 86% sensitive to detect LVEF less than 50% with specificity of 90.9%. Conclusions: The elevated serum level of pentraxin-3 and cardiac troponin-I in STEMI patients and their association with both LVEF and GLS support the concept that the magnitude of these biomarkers correlates to the severity of myocardium injury.展开更多
<strong>Background: </strong><span style="white-space:normal;font-size:10pt;font-family:;" "="">Physical activity has a cardinal role in preventing and treating cardiovascula...<strong>Background: </strong><span style="white-space:normal;font-size:10pt;font-family:;" "="">Physical activity has a cardinal role in preventing and treating cardiovascular diseases. Understanding the<b> </b>changes that occur to the cardiac muscle in athletes is still doubtful whether it is only an adaptation to exercise or a concealed pathological condition. Most of these changes are well documented in apparently healthy heart and characterized by cardiac enlargement with Brady-arrhythmias specially individuals participating in long distance runners with exercise capacity without signs of cardiovascular disease. <b>Methods: </b>The study searched the subclinical myocardial necrosis by comparing<b> </b>two groups of young marathon runners, both groups were chosen from Al Gizera youth center in January 2018. First group included adults above the age of 18 years and ran for 12 km. and the second was under 18 years and ran for about 8 km. Both groups were volunteered for this study. They are monitored carefully with blood pressure, heart rate and respiratory rate and their blood samples were collected pre- and post-race immediately for assessment of cardiac markers NTproBNP, Galectin-3 and cTnI. <b>Results: </b>All cardiac markers were elevated post exercise compared to that achieved in pre-exercise regardless age of athletes. Also, pre-exercise adult results were higher in galectin-3 and cTnI but not in proBNP while there is no difference in the acute response in both groups. These results revealed micro cardiac necrosis due to long run exercise with possible bad prognosis. <b>Conclusions:</b> It is important to develop risk assessment and prediction methods for screening the young athletes and consider the term athletic heart as a subclinical disorder rather than physiological adaptation.</span>展开更多
文摘Background: Pentraxin 3 is an inflammatory biomarker whose serum level is increased during acute myocardial infarction (AMI). The aim of this study was to measure the serum pentraxin-3 level in anterior ST-segment elevation myocardial infarction (STEMI), to investigate correlation with the left ventricular (LV) systolic function assessed by speckle tracking echocardiography, and compare with the well-established cardiac biomarkers of myocardial injury such as troponin-I. Methods: Serum pentraxin-3 level was measured by ELISA in 50 patients with anterior STEMI. LV strain was measured by speckle tracking echocardiography. The results were compared to twenty sex- and age-matched persons who had history of stable angina and normal LV ejection fraction (LVEF). Results: Serum level of pentraxin-3 was significantly higher in STEMI patients in comparison to the control group (8.3 ± 3.1 versus 3.4 ± 1.2 ng/ml, p 0.001). Average LV global longitudinal strain (GLS) was reduced in STEMI patients in comparison to control subjects (11.2 ± 2.4 versus 20.2 ± 2.1, p 0.001). In addition, there was a significant negative correlation between serum pentraxin-3 level and LVEF (r = -0.557, p 0.001) and the average LVGLS (r =-0.529, p 0.001). Serum pentraxin-3 cutoff value > 8.3 ng/ml had sensitivity of 81.8% and specificity of 86.4% to detect LVEF less than 50% (p 0.001). While, peak cardiac troponin-I level > 34 ng/ml was 86% sensitive to detect LVEF less than 50% with specificity of 90.9%. Conclusions: The elevated serum level of pentraxin-3 and cardiac troponin-I in STEMI patients and their association with both LVEF and GLS support the concept that the magnitude of these biomarkers correlates to the severity of myocardium injury.
文摘<strong>Background: </strong><span style="white-space:normal;font-size:10pt;font-family:;" "="">Physical activity has a cardinal role in preventing and treating cardiovascular diseases. Understanding the<b> </b>changes that occur to the cardiac muscle in athletes is still doubtful whether it is only an adaptation to exercise or a concealed pathological condition. Most of these changes are well documented in apparently healthy heart and characterized by cardiac enlargement with Brady-arrhythmias specially individuals participating in long distance runners with exercise capacity without signs of cardiovascular disease. <b>Methods: </b>The study searched the subclinical myocardial necrosis by comparing<b> </b>two groups of young marathon runners, both groups were chosen from Al Gizera youth center in January 2018. First group included adults above the age of 18 years and ran for 12 km. and the second was under 18 years and ran for about 8 km. Both groups were volunteered for this study. They are monitored carefully with blood pressure, heart rate and respiratory rate and their blood samples were collected pre- and post-race immediately for assessment of cardiac markers NTproBNP, Galectin-3 and cTnI. <b>Results: </b>All cardiac markers were elevated post exercise compared to that achieved in pre-exercise regardless age of athletes. Also, pre-exercise adult results were higher in galectin-3 and cTnI but not in proBNP while there is no difference in the acute response in both groups. These results revealed micro cardiac necrosis due to long run exercise with possible bad prognosis. <b>Conclusions:</b> It is important to develop risk assessment and prediction methods for screening the young athletes and consider the term athletic heart as a subclinical disorder rather than physiological adaptation.</span>
